2026-05-07T06:16:56Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/80722023-11-22T01:05:32Zcom_10259_5827com_10259_5086com_10259_2604col_10259_5828

Herreros-Villanueva, Marta Muñiz Rodríguez, Pilar García Girón, Carlos Cavia Saiz, Mónica Coma del Corral, María J. Background: Although there have been many studies on the p73 gene, some of its functions still remain unclear. There is little research on the relationship between p73 gene transcription and its protein expression and the response to certain drugs such as oxaliplatin and cetuximab, which are drugs currently used in colorectal cancer. The purpose of this study was to evaluate the impact of TAp73 expression on oxaliplatin and cetuximab-based chemotherapy in colorectal cancer cell lines with different K-Ras and B-Raf mutational status. Methods: TAp73 was analyzed in three colorectal tumor cell lines HT-29, SW-480 and Caco-2. mRNA TAp73 was determined using Real time PCR; TAp73 protein by immunoblotting and cell viability was analyzed by the MTT method. Results: We found that mRNA and TAp73 protein were decreased in cells treated with oxaliplatin (in monotherapy or combined with cetuximab) when B-Raf is mutated. This was statistically significant and was also associated with higher cell viability after the treatment. Conclusions: Here, for the first time we report, that there is a signaling loop between B-Raf activation and p73 function. Low expression of TAp73 in colorectal cancer cell lines with mutated B-Raf may be involved in the lack of response to oxaliplatin in monotherapy or combined with cetuximab. 2023-11-21 2023-11-21 2010-02 info:eu-repo/semantics/article http://hdl.handle.net/10259/8072 10.1186/1479-5876-8-15 1479-5876 eng Journal of Translational Medicine. 2010, V. 8, n. 1 https://doi.org/10.1186/1479-5876-8-15 http://creativecommons.org/licenses/by/3.0/ info:eu-repo/semantics/openAccess Attribution 3.0 Unported Springer Nature